Aytu Biopharma (AYTU) Net Cash Flow (2010 - 2026)

Aytu Biopharma (AYTU) has reported Net Cash Flow for 17 consecutive years, with -$3.3 million the latest figure, recorded in Q1 2026.

• On a quarterly basis, Net Cash Flow fell 48.76% year-over-year to -$3.3 million in Q1 2026; TTM through Mar 2026 was $8.5 million, a 638.25% increase from a year earlier, with the FY2025 full-year figure at $10.9 million, up 467.44% from the prior year.
• Net Cash Flow was -$3.3 million for Q1 2026 at Aytu Biopharma, down from -$2.6 million in the prior quarter.
• Over five years, Net Cash Flow peaked at $12.8 million in Q2 2025 and troughed at -$8.3 million in Q2 2022.
• A 5-year average of -$503647.1 and a median of -$316000.0 in 2023 frame the typical range for Net Cash Flow.
• The widest YoY moves for Net Cash Flow: up 5094.72% in 2025, down 1063.2% in 2025.
• Over 5 years, Net Cash Flow stood at -$4.3 million in 2022, then soared by 89.94% to -$435000.0 in 2023, then soared by 166.67% to $290000.0 in 2024, then tumbled by 998.28% to -$2.6 million in 2025, then dropped by 27.06% to -$3.3 million in 2026.
• The last three Net Cash Flow figures came in at -$3.3 million (Q1 2026), -$2.6 million (Q4 2025), and $1.7 million (Q3 2025), per Business Quant data.